<DOC>
	<DOCNO>NCT02323334</DOCNO>
	<brief_summary>This study involve single multiple dos LY3202626 evaluate effect LY3202626 body . There 4 part study . In Parts A B , single increase dos LY3202626 give capsule form . Part A also include itraconazole give orally solution . Part A last approximately 8-12 week . Part B last approximately 5-6 week . In Parts C D , participant dose multiple day study drug . Part C last approximately 11-14 week . Part D last approximately 11-14 week participant must Alzheimer 's Disease . Participants may enroll one part .</brief_summary>
	<brief_title>A Study LY3202626 Healthy Participants Participants With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>For Parts A , B , C , overtly healthy male female ( nonchildbearing potential ) , determine medical history physical examination Have body mass index ( BMI ) 18 32 kilogram per square meter ( kg/m^2 ) For Part D , present Mild Cognitive Impairment ( MCI ) due Alzheimer 's Disease ( AD ) mild moderate AD Have venous access sufficient allow blood sampling Are reliable willing make available duration study willing follow study procedure research unit policy Taking overthecounter prescription medication exception vitamins mineral Smoke 10 cigarette per day Are unwilling unable refrain eat food drinking beverage contain grapefruit grapefruit juice least 2 week prior first dose completion study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>